The observation that in advanced‐phase CML loss of function of SETD2 is most frequently nongenetic/nongenomic, hence reversible, prompted us to investigate the underlying mechanisms. This evidence concerns the gene SETD2 and chronic myelogenous leukemia, BCR-ABL1 positive.